Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1112-1121

  Welles, Lauri ^a   Seville, M Wayne ^a   Lietzau, Jill ^a   Pluda, James M ^a   Wyvill, Kathleen M ^a   Feuerstein, Irwin ^a   Figg, William D ^a   Lush, Richard ^a   Odom, Jeanne ^a   Wilson, Wyndham H ^a   Fajardo, Monina T ^a   Humphrey, Rachel W ^a   Feigal, Ellen ^a   Tuck, David ^a   Steinberg, Seth M ^a   Broder, Samuel ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CREATININE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG SAFETY; EOSINOPHILIA; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

EID: 0031911323     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1112     Document Type: Article

References (49)

1. Gill P, Akil B, Colletti P: Pulmonary Kaposi's sarcoma: Clinical findings and results of therapy. Am J Med 90:57-61, 1989
2. Meduri G, Stover D, Lee M: Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: Clinical, radiographic and pathologic manifestations. Am J Med 81:11-18, 1986
3. Groopman JE, Gottlieb MS, Goodman J, et al: Recombinant alpha-2 interferon for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100:671-676, 1984
4. Volberding PA, Abrams DI, Conant M, et al: Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103:335-338, 1985
5. Krown SE, Real FX, Cunningham-Rundles S, et al: Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 308:1071-1076, 1983
6. Gill PS, Rarick M, McCutchan JA, et al: Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am J Med 90:427-433, 1991
7. Gill PS, Espina BM, Muggia F, et al: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13:996-1003, 1995
8. Harrison M, Tomlinson D, Stewart S: Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-20, 1995
9. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997
10. Lee F-C, Mitsuyasu RT: Chemotherapy of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am 10:1051-1068, 1996
11. Gelmon K: The taxoids: Paclitaxel and docetaxel. Lancet 344: 1267-1272, 1994
12. Arbuck SG, Dorr A, Friedman MA: Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin North Am 8:121-140, 1994
13. Rowinsky E, Donehower P: Paclitaxel (Taxol). N Engl J Med 332:1004-1013, 1995
14. Saville MW, Lietzau J, Pluda JM, et al: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346:26-28, 1995
15. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
16. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
17. Seidman AD, Hochhauser D, Gollub M. et al: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
18. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 7:1201-1207, 1989
19. Krown S, Testa M, Huang J: Validation of the AIDS Clinical Trials Group (ACTG) staging classification for AIDS-associated Kaposi's sarcoma (AIDS/KS). Proc Am Soc Clin Oncol 15:303, 1996 (abstr)
20. Wiley T, Bekos E, Gaver R, et al: High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr Biomed Applic 621:231-238, 1993
21. D'Argenia D, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134, 1979
22. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
23. Slud EV, Byar DP, Green SB: A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data. Biometrics 40:587-600, 1984
24. Hryniuk W, Goodyear M: The calculation of received dose intensity. J Clin Oncol 8:1935-1937, 1990 (editorial)
25. Winston J, Klotman P: Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 7:1-7, 1996
26. Centers for Disease Control: Revision of the CDC surveillance definition for acquired immunodeficiency syndrome. MMWR 36:1S-15S, 1987
27. O'Brien W, Hartigan P, Martin D, et al: Changes in plasma HIV-1 RNA and CD4+ lymphocyte count relative to treatment and progression to AIDS. N Engl J Med 334:426-431, 1996
28. Saag M, Holodniy M, Kuritzkes D, et al: HIV viral load markers in clinical practice. Nat Med 2:625-629, 1996
29. Vadhan-Raj S, Wong G, Gnecco C, et al: Immunologic variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res 46:417-425, 1986
30. Rowinsky EK: Clinical pharmacology of Taxol. Monogr NCI 15:25-37, 1993
31. Kohler DR, Goldspiel BR: Paclitaxel (Taxol). Pharmacotherapy 14:3-34, 1994
32. Laubenstein L, Krigel RL, Odajnyk C, et al: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2:1115-1120, 1984
33. Gill PS, Miles SA, Mitsuyasu RT, et al: Phase I AIDS Clinical Trials Group (075) study of Adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 8:1695-1699, 1994
34. Bogner J, Kronawitter U, Rolinski B, et al: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 7:463-468, 1994
35. Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364, 1996
36. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has anti-angiogenic activity. Clin Cancer Res 2:1843-1849, 1996
37. Klauber N, Parangi S, Flynn E, et al: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57:81-86, 1997
38. Morris C, Gendelman R, Marrogi A, et al: Immunohistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma. Am J Pathol 148:1055-1063, 1996
39. Ensoli B, Morris B, Gendelman R, et al: Cytokine-mediated activation of Bcl-2 expression in Kaposi's sarcoma (KS) and synergy by HIV-1 Tat protein: Role in progression of AIDS-KS. J AIDS Hum Retrovirol, Abstracts of the Annual Meeting of the Institute of Human Virology, Baltimore, MD, September 7-13, 1996, p 22
40. Blagosklonny M, Schulte T, Nguyen P, et al: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56:1851-1854, 1996
41. Haldar S, Chintapalli J, Croce C: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255, 1996
42. Chang Y, Cesarman E, Pessin M, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994
43. Moore PS, Boshoff C, Weiss RA, et al: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-1744, 1996
44. Huang YQ, Li JJ, Kaplan MH, et al: Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 345:759-761, 1995
45. Whitby D, Howard MR, Tenant-Flowers M, et al: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346:799-802, 1995
46. Humphrey RW, O'Brien TR, Newcomb FM, et al: Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells (PBMCs): Association with KS and persistence in patients receiving anti-herpes drugs. Blood 88:297-301, 1996
47. Kuppermann B, Petty J, Richman D, et al: Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 115:575-582, 1993
48. Hakim FT, Cepeda R, Sung K, et al: Constraints on CD4 recovery post chemotherapy in adults: Thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 90:3789-3798, 1997
49. Gill P, Scadden D, Groopman J, et al: Low dose paclitaxel (Taxol) is highly effective in the treatment of patients with advanced AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 14:A35, 1997 (abstr)